News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,748 Results
Type
Article (39690)
Company Profile (247)
Press Release (658811)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204190)
Career Advice (2007)
Deals (35419)
Drug Delivery (95)
Drug Development (81045)
Employer Resources (173)
FDA (16180)
Job Trends (14859)
News (345212)
Policy (32536)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49444)
ALS (88)
Alzheimer's disease (1377)
Antibody-drug conjugate (ADC) (124)
Approvals (16185)
Artificial intelligence (252)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (278)
Cancer (2250)
Cardiovascular disease (173)
Career advice (1676)
Career pathing (30)
CAR-T (150)
Cell therapy (421)
Cervical cancer (19)
Clinical research (65979)
Collaboration (832)
Compensation (524)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (240)
Cystic fibrosis (100)
Data (2195)
Decentralized trials (2)
Denatured (18)
Depression (42)
Diabetes (270)
Diagnostics (6367)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86598)
Editorial (36)
Employer branding (21)
Employer resources (147)
Events (112369)
Executive appointments (722)
FDA (17426)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (746)
Gene editing (104)
Generative AI (19)
Gene therapy (301)
GLP-1 (707)
Government (4415)
Grass and pollen (4)
Guidances (59)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16507)
IRA (40)
Job creations (3632)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (153)
Machine learning (7)
Management (58)
Manufacturing (303)
MASH (66)
Medical device (13375)
Medtech (13380)
Mergers & acquisitions (19455)
Metabolic disorders (682)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1909)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (39)
Obesity (362)
Opinion (204)
Ovarian cancer (75)
Pain (85)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (110)
Peanut (46)
People (57300)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20552)
Phase II (29054)
Phase III (21648)
Pipeline (1184)
Policy (138)
Postmarket research (2563)
Preclinical (8739)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5908)
Recruiting (65)
Regulatory (22270)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (68)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3577)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (29)
Vaccines (685)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (171)
Last 7 days (858)
Last 30 days (2613)
Last 365 days (32811)
2025 (10587)
2024 (35219)
2023 (40077)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35020)
2017 (32111)
2016 (31485)
2015 (37553)
2014 (31325)
2013 (26351)
2012 (28575)
2011 (29268)
2010 (27330)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37836)
Australia (6185)
California (6099)
Canada (2008)
China (520)
Colorado (265)
Connecticut (272)
Delaware (146)
Europe (81264)
Florida (907)
Georgia (205)
Idaho (57)
Illinois (533)
India (25)
Indiana (306)
Iowa (11)
Japan (161)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (886)
Massachusetts (4549)
Michigan (219)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1719)
New Mexico (28)
New York (1735)
North Carolina (963)
North Dakota (8)
Northern California (2666)
Ohio (203)
Oklahoma (14)
Oregon (34)
Pennsylvania (1371)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (22)
South Dakota (1)
Southern California (2288)
Tennessee (101)
Texas (903)
United States (23008)
Utah (180)
Virginia (144)
Washington D.C. (61)
Washington State (549)
West Virginia (3)
Wisconsin (54)
698,748 Results for "novozymes inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Legacy Novozymes delivers solid last full-year results
In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROIC including goodwill before special items* of 16.5%.
February 1, 2024
·
2 min read
Deals
The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner
On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.
January 29, 2024
·
8 min read
Deals
Novozymes and Chr. Hansen announce name of future combined company; Novonesis
Novozymes and Chr. Hansen announced their future name ‘Novonesis’. The name reflects the beginning of an era of biosolutions where Novonesis will unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.
December 13, 2023
·
13 min read
Bio NC
Novozymes accelerates growth in Q3 and is on track to deliver on full-year expectations
October 26, 2023. Novozymes delivers 5% organic sales growth, an EBIT-margin of 25.5% before special items, and ROIC including goodwill of 16.3% before special items in the first nine months of the 2023 financial year.
October 26, 2023
·
5 min read
Business
Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook
Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the first half of the 2023 financial year.
August 9, 2023
·
5 min read
Bio NC
Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs
Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+.
September 4, 2023
·
3 min read
Business
Novozymes delivers stronger than expected Q1 results
In the first three months of the 2023 financial year, Novozymes delivers 5% organic sales growth, an EBIT-margin of 26.0% before special items, and ROIC including goodwill of 17.7% before special items.
April 26, 2023
·
4 min read
Press Releases
Synamics Therapeutics, AI-Driven Drug Discovery Startup, Attracts Former Novozymes Executives as Lead Investors
July 11, 2024
·
2 min read
Business
Novozymes delivers historically strong full-year results
In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before special items* of 17.9%.
January 26, 2023
·
4 min read
Novozymes invests in new UV technology from Danish Lyras
The biotech group Novozymes has invested in a new and energy-friendly filtration replacement from Danish Lyras.
January 5, 2023
·
4 min read
1 of 69,875
Next
